Advertisement
Australia markets closed
  • ALL ORDS

    8,416.60
    -57.70 (-0.68%)
     
  • ASX 200

    8,150.00
    -55.20 (-0.67%)
     
  • AUD/USD

    0.6799
    -0.0045 (-0.65%)
     
  • OIL

    74.45
    +0.74 (+1.00%)
     
  • GOLD

    2,673.20
    -6.00 (-0.22%)
     
  • Bitcoin AUD

    91,293.52
    -202.34 (-0.22%)
     
  • XRP AUD

    0.78
    -0.00 (-0.32%)
     
  • AUD/EUR

    0.6190
    -0.0007 (-0.12%)
     
  • AUD/NZD

    1.1031
    +0.0024 (+0.22%)
     
  • NZX 50

    12,619.94
    +47.28 (+0.38%)
     
  • NASDAQ

    20,035.02
    +241.67 (+1.22%)
     
  • FTSE

    8,280.63
    -1.89 (-0.02%)
     
  • Dow Jones

    42,352.75
    +341.16 (+0.81%)
     
  • DAX

    19,120.93
    +105.52 (+0.55%)
     
  • Hang Seng

    22,736.87
    +623.36 (+2.82%)
     
  • NIKKEI 225

    38,635.62
    +83.56 (+0.22%)
     

Alexium International Group Full Year 2024 Earnings: US$0.003 loss per share (vs US$0.005 loss in FY 2023)

Alexium International Group (ASX:AJX) Full Year 2024 Results

Key Financial Results

  • Revenue: US$5.89m (down 18% from FY 2023).

  • Net loss: US$2.76m (loss narrowed by 6.4% from FY 2023).

  • US$0.003 loss per share (improved from US$0.005 loss in FY 2023).

revenue-and-expenses-breakdown
revenue-and-expenses-breakdown

All figures shown in the chart above are for the trailing 12 month (TTM) period

In the last 12 months, the only revenue segment was Specialty Chemicals contributing US$5.89m. Notably, cost of sales worth US$3.25m amounted to 55% of total revenue thereby underscoring the impact on earnings. The largest operating expense was General & Administrative costs, amounting to US$3.55m (66% of total expenses). Explore how AJX's revenue and expenses shape its earnings.

Alexium International Group's share price is broadly unchanged from a week ago.

Risk Analysis

We don't want to rain on the parade too much, but we did also find 3 warning signs for Alexium International Group (2 can't be ignored!) that you need to be mindful of.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.